Literature DB >> 31241978

Neurohumoral interactions contributing to renal vasoconstriction and decreased renal blood flow in heart failure.

Rohit Ramchandra1,2, Daniel T Xing1,3, Marcus Matear1,4, Gavin Lambert5, Andrew M Allen4, Clive N May1.   

Abstract

In heart failure (HF), increases in renal sympathetic nerve activity (RSNA), renal norepinephrine spillover, and renin release cause renal vasoconstriction, which may contribute to the cardiorenal syndrome. To increase our understanding of the mechanisms causing renal vasoconstriction in HF, we investigated the interactions between the increased activity of the renal nerves and the renal release of norepinephrine and renin in an ovine pacing-induced model of HF compared with healthy sheep. In addition, we determined the level of renal angiotensin type-1 receptors and the renal vascular responsiveness to stimulation of the renal nerves and α1-adrenoceptors. In conscious sheep with mild HF (ejection fraction 35%-40%), renal blood flow (276 ± 13 to 185 ± 18 mL/min) and renal vascular conductance (3.8 ± 0.2 to 3.1 ± 0.2 mL·min-1·mmHg-1) were decreased compared with healthy sheep. There were increases in the burst frequency of RSNA (27%), renal norepinephrine spillover (377%), and plasma renin activity (141%), whereas the density of renal medullary angiotensin type-1 receptors decreased. In anesthetized sheep with HF, the renal vasoconstrictor responses to electrical stimulation of the renal nerves or to phenylephrine were attenuated. Irbesartan improved the responses to nerve stimulation, but not to phenylephrine, in HF and reduced the responses in normal sheep. In summary, in HF, the increases in renal norepinephrine spillover and plasma renin activity are augmented compared with the increase in RSNA. The vasoconstrictor effect of the increased renal norepinephrine and angiotensin II is offset by reduced levels of renal angiotensin type-1 receptors and reduced renal vasoconstrictor responsiveness to α1-adrenoceptor stimulation.

Entities:  

Keywords:  cardiorenal syndrome type 2; heart failure; renal spillover; renal sympathetic nerve activity

Mesh:

Substances:

Year:  2019        PMID: 31241978     DOI: 10.1152/ajpregu.00026.2019

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  6 in total

Review 1.  Comprehensive and Safe Decongestion in Acutely Decompensated Heart Failure.

Authors:  Jason Stencel; Indranee Rajapreyar; Rohan Samson; Thierry Le Jemtel
Journal:  Curr Heart Fail Rep       Date:  2022-09-01

Review 2.  Extracellular Vesicles and Their Relationship with the Heart-Kidney Axis, Uremia and Peritoneal Dialysis.

Authors:  Carolina Amaral Bueno Azevedo; Regiane Stafim da Cunha; Carolina Victoria Cruz Junho; Jessica Verônica da Silva; Andréa N Moreno-Amaral; Thyago Proença de Moraes; Marcela Sorelli Carneiro-Ramos; Andréa Emilia Marques Stinghen
Journal:  Toxins (Basel)       Date:  2021-11-04       Impact factor: 4.546

Review 3.  Acute Cardiorenal Syndrome: Models and Heart-Kidney Connectors.

Authors:  Yoshio Funahashi; Sheuli Chowdhury; Mahaba B Eiwaz; Michael P Hutchens
Journal:  Nephron       Date:  2020-08-19       Impact factor: 3.457

4.  Cardiac and Vascular α1-Adrenoceptors in Congestive Heart Failure: A Systematic Review.

Authors:  Gizem Kaykı-Mutlu; Olga Papazisi; Meindert Palmen; A H Jan Danser; Martin C Michel; Ebru Arioglu-Inan
Journal:  Cells       Date:  2020-11-04       Impact factor: 6.600

5.  Role of Renal Sympathetic Nerve Activity in Volatile Anesthesia's Effect on Renal Excretory Function.

Authors:  Micael Taavo; Mats Rundgren; Peter Frykholm; Anders Larsson; Stephanie Franzén; Karin Vargmar; Jean F Valarcher; Gerald F DiBona; Robert Frithiof
Journal:  Function (Oxf)       Date:  2021-08-20

Review 6.  Role and Mechanism of the Renin-Angiotensin-Aldosterone System in the Onset and Development of Cardiorenal Syndrome.

Authors:  Kexin Ma; Weifang Gao; Huazhou Xu; Wenjie Liang; Guoping Ma
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2022-01-24       Impact factor: 1.636

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.